Company
Every investor coverage indicates participated in a round hVIVO raised.
Companies hVIVO acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming hVIVO. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Biotech firm ENA Respiratory has contracted PPD and hVIVO to run Phase 2 trials of its INNA-051 nasal spray, which aims to prevent COVID-19 and other respiratory viral infections, after encouraging Phase 1 safety results.
Biotech firm ENA Respiratory has contracted research organisations PPD and hVIVO to run Phase 2 trials of its INNA-051 nasal spray, following encouraging Phase 1 safety results, with participant recruitment expected from January 2022.